NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.440
-0.040 (-1.15%)
At close: Sep 1, 2026, 4:00 PM EDT
3.450
+0.010 (0.29%)
Pre-market: Sep 2, 2026, 7:03 AM EDT
NRx Pharmaceuticals Revenue
NRx Pharmaceuticals had revenue of $1.10M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $3.39M. In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M.
Revenue (ttm)
$3.39M
Revenue Growth
n/a
P/S Ratio
43.85
Revenue / Employee
$117,034
Employees
29
Market Cap
148.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| MediWound | 11.86M |
| Equillium | 4.39M |
| Connect Biopharma Holdings | 2.95M |
| Milestone Pharmaceuticals | 2.34M |
| Kazia Therapeutics | 1.27M |
| Outlook Therapeutics | -1.16M |
NRXP News
- 16 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - GlobeNewsWire
- 19 days ago - NRx Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 19 days ago - NRx Pharmaceuticals Earnings release: Q2 2026 - Filings
- 22 days ago - NRx Pharmaceuticals Transcript: Status update - Transcripts
- 25 days ago - NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans - GlobeNewsWire
- 26 days ago - FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA - TheFly
- 26 days ago - FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval - GlobeNewsWire
- 2 months ago - NRx Pharmaceuticals issues response to Kadima statements - TheFly